Table 1—

Baseline characteristic of the tiotropium and placebo groups

TiotropiumPlacebo
Subjects914915
Males898 (98)904 (99)
Age yrs67.6±8.768.1±8.5
White ethnicity847 (93)823 (90)
Smoking status
 Current smoker263 (29)272 (30)
 Pack-yr history67.4±35.469.4±36.6
Duration of COPD yrs12.2±10.411.9±10.5
Baseline spirometry
 FEV1 L1.04±0.401.04±0.40
 FEV1 % pred35.6±12.635.6±12.6
 FEV1/FVC %47.9±11.547.7±11.1
Medication for COPD
 Inhaled β-agonist
  Any851 (93)864 (94)
  Nebulised237 (26)234 (26)
  Long-acting346 (38)351 (38)
 Ipratropium bromide
  Any735 (80)728 (80)
  Nebulised138 (15)157 (17)
 Corticosteroids
  Inhaled559 (61)531 (58)
  Oral94 (10)97 (11)
 Theophylline141 (15)118 (13)
 Leukotriene antagonist59 (6)53 (6)
 Home oxygen259 (28)272 (30)
  • Data are presented as n, n (%) or mean±sd. COPD: chronic obstructive pulmonary disease; FEV1: forced expiratory volume in one second; % pred: % predicted; FVC: forced vital capacity. Data taken from 8.